Retrospective analysis shows improved outcomes with combined therapies in advanced pancreatic cancer, suggesting potential for better management.
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors. Patients who develop PDAC with locally advanced pancreatic cancer (LAPC) or metastases have an especially poor prognosis[1][1]. Although there have been improvements in systemic therapy, long-term disease control is
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: